CHTT227A12301: A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease (INVEST HD)

Principal Investigator

Dr Richard Armstrong

Contact us

Email: dendron@ouh.nhs.uk

IRAS number

1013249